【阿斯利康(AZN.US)宣布FLAURA2研究积极结果 奥希替尼联合方案助力肺癌OS改善】智通财经APP获悉,7月21日,阿斯利康(AZN.US)宣布III期FLAURA2研究最终总生存期(OS)分析取得积极结果:在一线治疗局部晚期或转移性表皮生长因子受体突变(EGFRm)非小细胞肺癌(NSCLC)患者中,奥希替尼联合培美曲塞和铂类化疗相较于奥希替尼单药治疗在关键次要终点OS方面显示出统计学显著和临床意义的改善。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.